Abstract
Patients with widespread cancer respond initially to combination chemotherapy, immunotherapy, and / or radiotherapy, but most relapse with chemoresistant disease. Novel methods of killing resistant neoplastic stem cells are needed. One such approach is therapy with targeted toxins composed of tumor cell selective ligands covalently linked to group I peptide toxins (group II and III peptide toxins act on the cell surface). The targeted toxin is delivered to the cell by a tumor selective ligand. Once bound, the ligandreceptor complex is internalized. The catalytic domain escapes to the cytosol. The toxin then enzymatically modifies a critical cell function (protein synthesis, p21 Rho activity, protein kinase signaling, cyclic AMP signaling or others). The irreversibly damaged cells fails to divide and, eventually, undergoes lysis or programmed cell death. Targeted peptide toxins used to date in the treatment of chemotherapy refractory cancers include ricin toxin, Pseudomonas exotoxin, pokeweed antiviral protein, saporin, gelonin and diphtheria toxin. In this review, we have focused on the applications of genetically engineered diphtheria toxin for cancer therapy.
Keywords: Diphtheria Fusion Protein Therapy, Chemoresistant Malignancies, Pseudomonas exotoxin, saporin, gelonin, diphtheria toxin, genetically engineered diphtheria toxin, cancer therapy, corynebacterium diphtheriae, iymphocytic leukemia cll
Current Cancer Drug Targets
Title: Diphtheria Fusion Protein Therapy of Chemoresistant Malignancies
Volume: 2 Issue: 1
Author(s): Arthur E. Frankel, Patrick Rossi, Timothy M. Kuzel and Francine Foss
Affiliation:
Keywords: Diphtheria Fusion Protein Therapy, Chemoresistant Malignancies, Pseudomonas exotoxin, saporin, gelonin, diphtheria toxin, genetically engineered diphtheria toxin, cancer therapy, corynebacterium diphtheriae, iymphocytic leukemia cll
Abstract: Patients with widespread cancer respond initially to combination chemotherapy, immunotherapy, and / or radiotherapy, but most relapse with chemoresistant disease. Novel methods of killing resistant neoplastic stem cells are needed. One such approach is therapy with targeted toxins composed of tumor cell selective ligands covalently linked to group I peptide toxins (group II and III peptide toxins act on the cell surface). The targeted toxin is delivered to the cell by a tumor selective ligand. Once bound, the ligandreceptor complex is internalized. The catalytic domain escapes to the cytosol. The toxin then enzymatically modifies a critical cell function (protein synthesis, p21 Rho activity, protein kinase signaling, cyclic AMP signaling or others). The irreversibly damaged cells fails to divide and, eventually, undergoes lysis or programmed cell death. Targeted peptide toxins used to date in the treatment of chemotherapy refractory cancers include ricin toxin, Pseudomonas exotoxin, pokeweed antiviral protein, saporin, gelonin and diphtheria toxin. In this review, we have focused on the applications of genetically engineered diphtheria toxin for cancer therapy.
Export Options
About this article
Cite this article as:
Frankel E. Arthur, Rossi Patrick, Kuzel M. Timothy and Foss Francine, Diphtheria Fusion Protein Therapy of Chemoresistant Malignancies, Current Cancer Drug Targets 2002; 2 (1) . https://dx.doi.org/10.2174/1568009023333944
DOI https://dx.doi.org/10.2174/1568009023333944 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Innovative Cancer Drug Targets: A New Horizon in Oncology
Cancer remains one of the most challenging diseases, with its complexity and adaptability necessitating continuous research efforts into more effective and targeted therapeutic approaches. Recent years have witnessed significant progress in understanding the molecular and genetic basis of cancer, leading to the identification of novel drug targets. These include, but ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Trends and Prospects of Plant Proteases in Therapeutics
Current Medicinal Chemistry Peptidic Tumor Targeting Agents: The Road from Phage Display Peptide Selections to Clinical Applications
Current Pharmaceutical Design Clinical Pharmacokinetics of Systemically Administered Antimycotics
Current Clinical Pharmacology Peptide-Based Subunit Nanovaccines
Current Drug Delivery Serine Protease Inhibitor Kazal Type 1 (SPINK1): Beyond the Trypsin Inhibitor
Current Enzyme Inhibition Reactive Oxygen Species in Pathogenesis of Atherosclerosis
Current Pharmaceutical Design Cyclosporine A Suppresses the Malignant Progression of Oral Squamous Cell Carcinoma in vitro
Anti-Cancer Agents in Medicinal Chemistry Sucrose Hydrolytic Enzymes: Old Enzymes for New Uses as Biocatalysts for Medical Applications
Current Topics in Medicinal Chemistry Targeting CCK Receptors in Human Cancers
Current Topics in Medicinal Chemistry Novel Mechanisms of Anticancer Activities of Green Tea Component Epigallocatechin- 3-Gallate
Anti-Cancer Agents in Medicinal Chemistry Mechanisms of Corticosteroid Resistance in Severe Asthma and Chronic Obstructive Pulmonary Disease (COPD)
Current Pharmaceutical Design Passive Smoking and Coronary Heart Disease
Current Vascular Pharmacology Cardioprotective effects of Aronia melanocarpa anthocynanins. From laboratory experiments to clinical practice.
Current Pharmaceutical Design Oxidative Stress Modulation and Radiosensitizing Effect of Quinoxaline-1,4-Dioxides Derivatives
Anti-Cancer Agents in Medicinal Chemistry The Chemistry and Pharmacology of Genistein
The Natural Products Journal Patent Selections
Recent Patents on Mechanical Engineering Clinical Value of 99mTc-octreotide Scintigraphy and Planar X-ray Mammography for the Diagnosis of Breast Cancer
Current Medical Imaging Neuroimaging of Cancer Patients for Psychosocial Support and Patient Care
Current Medical Imaging The Promising Signatures of Circulating microRNA-145 in Epithelial Ovarian Cancer Patients
MicroRNA Telomere Recombination and the ALT Pathway: A Therapeutic Perspective for Cancer
Current Pharmaceutical Design